AdipoART
Commercial- Indications
- Osteoarthritis
Company intelligence / Profile preview
GaiaCell has developed GMP-certified cellular therapies using mesenchymal stem/stromal cells for orthopedic, hemato-oncological, pulmonological, and other indications. Their approach offers alternatives to invasive procedures with a focus on safety, efficacy, immunomodulation, and tissue regeneration. The company provides both autologous and allogeneic treatments with dosed administration of 15–20 million MSCs per procedure. Clinical results emphasize improved quality of life through pain reduction and functional restoration in treated patients[1][2].
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GaiaCell.